Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
- Interventions
- Drug: CrenolanibDrug: CytarabineDrug: Placebo Oral TabletDrug: MitoxantroneDrug: FludarabineDrug: IdarubicinDrug: G-CSF
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 322
- Registration Number
- NCT03250338
- Locations
- 🇺🇸
Kansas University, Kansas City, Kansas, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇨🇦University of Alberta, Edmonton, Alberta, Canada
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid Leukemia
- Interventions
- Drug: CytarabineDrug: DecitabineDrug: IdarubicinOther: Laboratory Biomarker AnalysisDrug: Liposome-encapsulated Daunorubicin-CytarabineOther: Quality-of-Life AssessmentDrug: AzacitidineOther: Questionnaire AdministrationDrug: VenetoclaxDrug: glasdegib
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 75
- Registration Number
- NCT03226418
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Recurrent Acute Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT03214562
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
- Conditions
- Mature B-cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 650
- Registration Number
- NCT03206671
- Locations
- 🇫🇮
Turku University Hospital, Paediatric and Adolescent Haematology and Oncology, Turku, Finland
🇨🇭Universitäts-Kinderspital, Pädiatrische Onkologie, Zürich, Switzerland
🇨🇭Kinderspital Pädiatrische Hämatologie/ Onkologie, Luzern, Switzerland
iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- University of Florida
- Registration Number
- NCT03207334
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT03194932
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Lucille Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaRelapse Leukemia
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 48
- Registration Number
- NCT03181815
- Locations
- 🇨🇳
Liang Wang, Guangzhou, Guangdong, China
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- Drug: AzacitidineDrug: DecitabineDrug: CytarabineDrug: DaunorubicinDrug: EtoposideCombination Product: ITMHADrug: IdarubicinDrug: FludarabineDrug: MitoxantroneDrug: Erwinia asparaginaseDrug: SorafenibDrug: G-CSFDrug: DexrazoxaneDrug: Asparaginase Erwinia Chrysanthemi, Recombinant-RywnBiological: Stem Cell Transplant
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 206
- Registration Number
- NCT03164057
- Locations
- 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸Children's Hospital of Central California, Madera, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Conditions
- B Acute Lymphoblastic Leukemia
- Interventions
- Drug: AllopurinolDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: Vincristine SulfateDrug: DexamethasoneDrug: Pegylated L-AsparaginaseDrug: MethotrexateProcedure: Bone Marrow Aspiration and BiopsyDrug: CyclophosphamideDrug: MercaptopurineBiological: RituximabDrug: ThioguanineDrug: DoxorubicinOther: Laboratory Biomarker AnalysisBiological: Inotuzumab Ozogamicin
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 310
- Registration Number
- NCT03150693
- Locations
- 🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
🇺🇸Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia with BCR-ABL1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT03147612
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.